The MARK3 (Microtubule Affinity-Regulating Kinase 3) antibody is a tool used to study the MARK3 protein, a serine/threonine kinase belonging to the PAR1/MARK family. MARK3 plays critical roles in cell polarity, microtubule dynamics, and signal transduction by phosphorylating microtubule-associated proteins, such as tau, which influences their binding to microtubules. Dysregulation of MARK3 has been implicated in neurological disorders (e.g., Alzheimer’s disease via tau hyperphosphorylation) and cancers, where it may modulate cell proliferation, migration, and apoptosis. Researchers employ MARK3 antibodies in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect MARK3 expression, localization, and activity in cellular and tissue samples. These antibodies are also used to explore MARK3's interactions with signaling pathways, including the LKB1-AMPK axis, and its role in diseases. Commercial MARK3 antibodies are typically raised against specific epitopes (e.g., N-terminal catalytic domains or C-terminal regulatory regions) and validated for specificity across human, mouse, and rat models. Recent studies highlight its potential as a therapeutic target, driving interest in inhibitors and functional studies. However, variability in antibody performance (e.g., cross-reactivity with other PAR1 kinases) necessitates careful validation for experimental accuracy.